The Full Wiki

More info on Astellas Pharma

Astellas Pharma: Wikis

  
  

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

Astellas Pharma Inc.
Type Public KK (TYO: 4503)
Founded 2005 (from merger)
Headquarters Tokyo, Japan
Key people Masafumi Nogimori, President & CEO
Industry Pharmaceuticals
Revenue ¥ 972,586 million JPY (FY 2007)
Net income ¥ 177,437 million JPY (FY 2007)
Employees 13,900 (2007)
Website www.astellas.com

Astellas Pharma Inc. (アステラス製薬株式会社 Asuterasu Seiyaku Kabushiki-gaisha?, TYO: 4503) is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. (山之内製薬株式会社 Yamanouchi Seiyaku Kabushiki-gaisha?) and Fujisawa Pharmaceutical Co., Ltd. (藤沢薬品工業株式会社 Fujisawa Yakuhin Kōgyō Kabushiki-gaisha?).

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.

Contents

History

Fujisawa Shoten was started in 1894 by Tomokichi Fujisawa in Osaka, and was renamed Fujisawa Pharmaceutical Co. in 1943.

Yamanouchi Yakuhin Shokai was started in 1923 by Kenji Yamanouchi in Osaka. The company was renamed Yamanouchi Pharmaceutical Co. in 1940 and moved to Tokyo in 1942.

Both companies started their overseas expansion at about the same time, opening offices in Taiwan in 1962 and 1963, respectively, and in the United States and Europe from 1977 onwards. Fujisawa acquired Lyphomed in 1990 and thereafter established its US R&D centre in Deerfield, Illinois. Yamanouchi's R&D centre in Leiderdorp was established with the acquisition of the pharmaceutical division of Royal Gist Brocades in 1991.

Fujisawa and Yamanouchi combined in a "merger of equals," forming Astellas Pharma on 1 April 2005.

At least some of its older products continue to be distributed under the original brand, ostensibly due to high brand-name recognition.[1]

Products

Some of the key products produced by Astellas include:

References

  1. ^ "Yamanouchi Pimafucin (natamycin) product line manufactured at least up to 11/2007"

External links








Got something to say? Make a comment.
Your name
Your email address
Message